Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADAPT-HEM: Biomarker-Selected Dual-Target CAR-T in R/R Hematologic Malignancies
NCT07523555Phase 2Recruiting
- Sponsor
- Biotech Pharmaceutical
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 2, open-label trial in acute lymphoblastic leukemia (ALL), non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) and 8 more (8 arms), sponsored by Biotech Pharmaceutical. Primary endpoints: Dose-limiting toxicities at 28 days and Cytokine release syndrome at 28 days. Started Mar 2026; status: recruiting.
02
Conditions
acute lymphoblastic leukemia (ALL)non-Hodgkin lymphoma (NHL)chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07523555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07523555.